Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,081 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma.
Kobayashi Y, Ando K, Imaizumi Y, Sakamoto H, Kitanosono H, Taguchi M, Mishima H, Kinoshita A, Bekytbek S, Baba M, Kato T, Horai M, Itonaga H, Sato S, Yoshiura KI, Miyazaki Y. Kobayashi Y, et al. Among authors: sakamoto h. Leuk Lymphoma. 2024 Dec;65(14):2116-2128. doi: 10.1080/10428194.2024.2393258. Epub 2024 Sep 1. Leuk Lymphoma. 2024. PMID: 39219309
[Ectopic pulmonary calcification after parathyroidectomy in multiple myeloma].
Ando K, Imaizumi Y, Yamamoto K, Tanaka M, Zaizen Y, Taguchi M, Sakaki C, Ichinose M, Furumoto T, Hashimoto M, Fujioka M, Sakamoto H, Hourai M, Itonaga H, Sato S, Sawayama Y, Hata T, Mukae H, Fukuoka J, Inoue D, Miyazaki Y. Ando K, et al. Among authors: sakamoto h. Rinsho Ketsueki. 2019;60(7):785-790. doi: 10.11406/rinketsu.60.785. Rinsho Ketsueki. 2019. PMID: 31391367 Japanese.
Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
Sakamoto H, Itonaga H, Sawayama Y, Furumoto T, Fujioka M, Chiwata M, Toriyama E, Kasai S, Nakashima J, Horai M, Kato T, Sato S, Ando K, Taguchi J, Imaizumi Y, Yoshida S, Hata T, Moriuchi Y, Miyazaki Y. Sakamoto H, et al. Hematol Oncol. 2020 Apr;38(2):162-170. doi: 10.1002/hon.2712. Epub 2020 Jan 26. Hematol Oncol. 2020. PMID: 31922287
Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
Chiwata M, Itonaga H, Sato S, Hashimoto M, Fujioka M, Kasai S, Sakamoto H, Toriyama E, Nakashima J, Kamijo R, Kitanosono H, Kobayashi Y, Horai M, Taguchi M, Matsuo M, Makiyama J, Takasaki Y, Matsuo E, Horio K, Ando K, Sawayama Y, Taguchi J, Kawaguchi Y, Tsushima H, Imanishi D, Imaizumi Y, Yoshida S, Jo T, Nonaka H, Moriuchi Y, Nagai K, Yokota KI, Hata T, Miyazaki Y. Chiwata M, et al. Among authors: sakamoto h. Intern Med. 2021 Jul 15;60(14):2207-2216. doi: 10.2169/internalmedicine.6620-20. Epub 2021 Feb 22. Intern Med. 2021. PMID: 33612681 Free PMC article.
The response-guided ATG treatment provides a survival benefit and KPS recovery for patients with steroid refractory acute GVHD: The Nagasaki Transplant Group Experience.
Fujioka M, Itonaga H, Furumoto T, Kasai S, Sakamoto H, Kitanosono H, Kato T, Horai M, Sato S, Sawayama Y, Taguchi J, Imaizumi Y, Hata T, Yoshida S, Moriuchi Y, Miyazaki Y. Fujioka M, et al. Among authors: sakamoto h. Transpl Immunol. 2021 Aug;67:101417. doi: 10.1016/j.trim.2021.101417. Epub 2021 May 28. Transpl Immunol. 2021. PMID: 34058354
3,081 results